Literature DB >> 11014672

Field expansion for homonymous hemianopia by optically induced peripheral exotropia.

E Peli1.   

Abstract

PURPOSE: To describe a novel method for prism correction of hemianopia that provides field-of-view expansion in a convenient and functional format and to evaluate initial clinical application.
METHOD: To expand the upper quadrant of the field, a high power prism segment (30-40delta) is placed base-out across the upper part of the spectacle lens, on the side of the loss, at about the level of the limbus. A similar prism segment at the lower part of the lens is used to treat the lower field. The peripheral location of the prisms causes peripheral exotropia. As a result a scene segment as high as the vertical span of the prism is shifted laterally by 15 to 20 degrees relative to the view of the other eye. At the edge of the hemianopic field loss, objects that would fall in the scotoma of one eye are seen through the prism in the other eye, providing a simultaneous awareness of details within the otherwise absent field-of-view. An approach for fitting the system to patients with abnormal binocular vision (strabismus and amblyopia, with or without diplopia) is discussed as well. The effect of the prisms was evaluated in a noncomparative case series (12 patients).
RESULTS: The field expansion is provided at any position of lateral gaze, including gaze away from the side of the scotoma. The effect of this technique on field expansion was demonstrated using standard binocular perimetry. Most patients reported substantial improvement in function and in obstacle avoidance.
CONCLUSION: A novel method for the optical treatment of hemianopia was developed and tested. It was found to be effective in expanding the field and helping patients' mobility.

Entities:  

Mesh:

Year:  2000        PMID: 11014672     DOI: 10.1097/00006324-200009000-00006

Source DB:  PubMed          Journal:  Optom Vis Sci        ISSN: 1040-5488            Impact factor:   1.973


  51 in total

1.  A Feedback-Controlled Interface for Treadmill Locomotion in Virtual Environments.

Authors:  Lee Lichtenstein; James Barabas; Russell L Woods; Eli Peli
Journal:  ACM Trans Appl Percept       Date:  2007-01       Impact factor: 1.550

2.  Randomized crossover clinical trial of real and sham peripheral prism glasses for hemianopia.

Authors:  Alex R Bowers; Karen Keeney; Eli Peli
Journal:  JAMA Ophthalmol       Date:  2014-02       Impact factor: 7.389

3.  DLP-based dichoptic vision test system.

Authors:  Russell L Woods; Henry L Apfelbaum; Eli Peli
Journal:  J Biomed Opt       Date:  2010 Jan-Feb       Impact factor: 3.170

4.  Field Expansion for Acquired Monocular Vision Using a Multiplexing Prism.

Authors:  Jae-Hyun Jung; Eli Peli
Journal:  Optom Vis Sci       Date:  2018-09       Impact factor: 1.973

5.  Extended wearing trial of Trifield lens device for 'tunnel vision'.

Authors:  Russell L Woods; Robert G Giorgi; Eliot L Berson; Eli Peli
Journal:  Ophthalmic Physiol Opt       Date:  2010-05       Impact factor: 3.117

6.  Multiplexing Prisms for Field Expansion.

Authors:  Eli Peli; Jae-Hyun Jung
Journal:  Optom Vis Sci       Date:  2017-08       Impact factor: 1.973

7.  Bitemporal hemianopia; its unique binocular complexities and a novel remedy.

Authors:  Eli Peli; PremNandhini Satgunam
Journal:  Ophthalmic Physiol Opt       Date:  2014-03       Impact factor: 3.117

8.  Driving with hemianopia, I: Detection performance in a driving simulator.

Authors:  Alex R Bowers; Aaron J Mandel; Robert B Goldstein; Eli Peli
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-07-15       Impact factor: 4.799

Review 9.  Relearning to See in Cortical Blindness.

Authors:  Michael D Melnick; Duje Tadin; Krystel R Huxlin
Journal:  Neuroscientist       Date:  2015-12-10       Impact factor: 7.519

Review 10.  Acceptance and use of health information technology by community-dwelling elders.

Authors:  Shira H Fischer; Daniel David; Bradley H Crotty; Meghan Dierks; Charles Safran
Journal:  Int J Med Inform       Date:  2014-06-16       Impact factor: 4.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.